Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Certolizumab Pegol (CDP870) for Rheumatoid Arthritis in Adults." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/432341/2/repview. Accessed 15 May 2024.
Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/432341/2/repview. Accessed May 15, 2024.
Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/432341/2/repview
Certolizumab Pegol (CDP870) for Rheumatoid Arthritis in Adults [Internet]. In: Cochrane Abstracts. [cited 2024 May 15]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/432341/2/repview.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
ID - 432341
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/432341/2/repview
DB - Evidence Central
DP - Unbound Medicine
ER -